Abstract
We have previously shown that a long noncoding RNA transcript Heg is negatively correlated with TSH receptor autoantibodies (TRAb) in patients with untreated Graves' disease and with CD14 mRNA in treated patients and controls. Thus patients with high concentrations of Heg RNA have low levels of TRAb or CD14 mRNA, respectively. Here we show that an additional factor, gene expression of Cdk1 in mononuclear cells, is positively related to concentrations of TRAb in patients with untreated Graves' disease. Cdk1 mRNA is very important for regulation of cell cycle activity. It is well known that TRAb decrease significantly during treatment with antithyroid drugs. This decrease during treatment cannot be explained by Heg RNA, which remains unchanged. Cdk1 mRNA decreased significantly during treatment to values below values obtained in normal subjects. Thus both Heg RNA and Cdk1 mRNA may influence the level of TSH receptor autoantibodies but by different mechanisms.
Highlights
We have previously shown that a long non-coding RNA transcript Heg in Mononuclear cells TSH receptor autoantibodies (TRAb) (MNC) (GenBank EU137727) is negatively correlated with TRAb in patients with early and untreated Graves’ disease and with CD14 mRNA in treated patients and in normal subjects
Cdk1 mRNA was positively related to TRAb (P < 0.002), and including Cdk1 RNA in the regression analysis increased the r value from −0.61 to −0.83 (r = −0.83; P < 0.001): log10TRAb IU/l = 1.209 − 12.652 × Heg RNA amol
A noncoding RNA transcript Heg is negatively related to TRAb in untreated patients with Graves’ disease and to CD14 mRNA in treated patients and controls
Summary
We have previously shown that a long non-coding RNA transcript Heg in MNC (GenBank EU137727) is negatively correlated with TRAb in patients with early and untreated Graves’ disease and with CD14 mRNA in treated patients and in normal subjects. Transfection studies with fragments of Heg (exogenous Heg) decreased CD14 mRNA [1] and increased TLR7 and INF-γ mRNA in MNC (unpublished results). TRAb decrease during treatment with antithyroid drugs. The primary aim of the present study was to examine if changes in TRAb during antithyroid treatment were related to changes in Heg RNA and CDl4 mRNA. We wanted to examine if TRAb was related to Cdk mRNA, which is an important factor for regulation of cell cycle activity [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
